As the House Energy and Commerce Committee prepares to consider a legislative provision (H.R. 3561) that would reduce payments for drug administration services furnished in off-campus provider-based departments, the AHA and other national hospital groups reiterated to committee leaders their opposition to the proposal and to site-neutral policies in general, which fail to account for the fundamental differences between hospital outpatient departments (HOPDs) and other ambulatory care sites. 

“It is important to note that HOPDs treat patients who are sicker and have more chronic conditions than those treated in physician offices or ambulatory surgical centers, as they are better equipped to handle complications and emergencies,” the letter notes. The committee is scheduled to consider H.R. 3561 tomorrow.

AHA also released a fact sheet highlighting three site-neutral proposals being considered by the committee and their estimated impact on Medicare reimbursement to hospitals and health systems; the estimates should not be combined because the legislative proposals contain some overlap. 

Perspective
Public
Approximately 35 million Americans are enrolled in Medicare Advantage plans in 2026, and that number is expected to grow to about 45 million MA enrollees by…
Headline
The Centers for Medicare & Medicaid Services has released details on downloading its upcoming fiscal year 2025 Program for Evaluating Payment Patterns…
Headline
The Department of Health and Human Services Administration for Community Living has launched the first phase of its Health at Home Challenge, a competition to…
Headline
The AHA shared the following statement with the media in response to a report released May 7 by Families USA.   “This report is long on rhetoric and…
Headline
The AHA May 7 wrote to House and Senate lawmakers in support of the Medicare Advantage Improvement Act (H.R. 8375/S. 4384), bipartisan and bicameral…
Headline
The Centers for Medicare & Medicaid Services announced May 6 that it will provide access to certain glucagon-like peptide-1 (GLP-1) medications to eligible…